Document Detail


Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy.
MedLine Citation:
PMID:  23212806     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Albuminuria has been shown to be associated with mortality and cardiovascular events, independent of traditional cardiovascular risk factors. This suggests that albuminuria may not just represent glomerular damage, but may be a marker of more diffuse endothelial dysfunction. We investigated the relationship between urinary albumin levels after an acute coronary syndrome and cardiovascular outcomes in statin treated subjects after acute coronary syndromes (ACS). Furthermore we assessed the effect of intensive statin treatment on albuminuria among patients in the PROVE IT-TIMI 22 trial, in which patients who had been hospitalized with ACS were randomized to pravastatin 40 mg (standard therapy) or atorvastatin 80 mg daily (intensive therapy). In univariate analyses, increasing urine albumin concentration was associated with increased risk of myocardial infarction, stroke, heart failure, and composite of death, myocardial infarction and stroke at 2 years. However, in a multivariable model containing traditional cardiovascular risk factors, albuminuria was not an independent predictor of the primary PROVE IT endpoint of death, myocardial infarction, unstable angina, revascularization and stroke, and was only an independent predictor of all-cause mortality at urinary albumin concentration >300 mcg/ml. There was no significant change in urinary albumin concentration from enrolment to end of study in either the standard or intensive statin therapy groups, and no significant difference between treatment groups. Our results suggest that after an acute coronary syndrome in statin treated patients, microalbuminuria may reflect traditional cardiovascular risk factor burden and offer little prognostic information independent of those factors.
Authors:
Babak Nazer; Kausik K Ray; Sabina A Murphy; C Michael Gibson; Christopher P Cannon
Related Documents :
24790796 - Stroke prevention in atrial fibrillation: commentary regarding the aan's evidence-based...
18926146 - A randomized controlled trial to evaluate the safety and efficacy of cardiac contractil...
194506 - Effect of isometric handgrip on systolic time intervals in patients with ischemic heart...
9087586 - Measurement of intraventricular pressure and cardiac performance in the intact closed-c...
22548966 - Alterations in echocardiographic and electrocardiographic features in japanese professi...
21613426 - The toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-5
Journal Detail:
Title:  Journal of thrombosis and thrombolysis     Volume:  -     ISSN:  1573-742X     ISO Abbreviation:  J. Thromb. Thrombolysis     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9502018     Medline TA:  J Thromb Thrombolysis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Division of Cardiology, University of California, San Francisco, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  APC resistance due to Factor V Leiden is not related to baseline inflammatory mediators or survival ...
Next Document:  Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Contr...